Renascience Inc. (TSE: 4889)
Health Care · Pharmaceuticals · JP
¥1,032.00
-6.44% today · -52.4% 1Y
Renascience Inc. (TSE: 4889) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $89.79M and employs 3 people.
Over the last twelve months the share price has lost 52.4%, trading between 1.00K and 2.32K.
Tweenvest scores Renascience Inc. across four factors: quality 42/100, value 57/100, growth 0/100. Its strongest factor is value.
4889 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $89.79M
- Revenue (TTM)
- $418.35K
- P/E
- —
- EPS
- -24.12
- Dividend yield
- —
- Beta (5Y)
- 1.71
- 52-week high
- ¥2,320.00
- 52-week low
- ¥1,000.00
- Avg volume (3M)
- —
- Shares outstanding
- 13.78M
- Employees
- 3
- Next earnings
- —
About Renascience Inc.
Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.
- ISIN
- JP3981100005
- Founded
- 2000
- Listed since
- Sep 24, 2021
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AlzeCure Pharma AB (publ)OM: ALZCUR | $93.23M | Skr7.10 | +5.03% |
| Rani Therapeutics Holdings, Inc.NasdaqGM: RANI | $92.22M | $0.77 | -3.65% |
| Stella Pharma CorporationTSE: 4888 | $92.15M | ¥394.00 | -7.51% |
| Shree Ganesh Remedies LimitedBSE: 540737 | $90.37M | Rs681.25 | -1.72% |
| Dong Sung Bio Pharm.Co.,Ltd.KOSE: A002210 | $89.60M | ₩1,283.00 | +0.39% |
| Neumora Therapeutics, Inc.NasdaqGS: NMRA | $89.38M | $0.45 | -5.82% |
| Dar Al Dawa Development and Investment Co. Ltd.ASE: DADI | $88.16M | JD1.25 | +1.63% |
| Hyphens Pharma International LimitedCatalist: 1J5 | $88.02M | S$0.37 | +2.82% |
Figures last refreshed Oct 11, 2026.